Floatz logo

GLUCAGON-LIKE PEPTIDE II

Short Bowel Syndrome

protein_peptideN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Short Bowel Syndrome cohort.

Asset / SponsorPhaseRating
Genotropin
Northwestern University
Phase 4BB
Glepaglutide
Zealand Pharma
Phase 3B
Loperamide
Odense University Hospital
Phase 3B
Apraglutide
VectivBio AG
Phase 2B
Crofelemer
Napo Therapeutics, S.p.A.
Phase 2CCC
Mono-[2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-6-chromanyl] succinate polyethylene glycol monoester
Boston Children's Hospital
Phase 2CCC
Glucagon-Like Peptide 2
Alberta Children's Hospital
Phase 1/2CCC
fe203799
GlyPharma Therapeutics
Phase 1/2NR

Same molecule, other indications

GLUCAGON-LIKE PEPTIDE II is also rated in:

spinal muscular atrophyDormant
D
Indicative ·
30 / 100
View asset →
cerebral palsyDormant
D
Indicative ·
30 / 100
View asset →
Duchenne muscular dystrophyDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →